BRIEF-Roche Presents New Phase Iii One-Year Data For Vamikibart In Uveitic Macular Edema

3

Oct 10 (Reuters) – Roche Holding AG: * ROCHE PRESENTS NEW PHASE III ONE-YEAR DATA FOR VAMIKIBART IN UVEITIC MACULAR EDEMA (UME), A SERIOUS CAUSE OF VISION LOSS * ROCHE HOLDING AG – VAMIKIBART

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)